ReviewCancers2024
Glioma-Immune Cell Crosstalk in Tumor Progression.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Neural Crest-Derived Stem Cell Secretomes and Extracellular Vesicles Disrupt Glioblastoma through Dual-Pathway Inflammatory Rebalancing.Stem cell reviews and reports · 2026Article
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- Consensus statement on microglial and macrophage functions in gliomas.Acta neuropathologica · 2026Review
- Nervous and immune system crosstalk shapes cancer progression and treatment response.Discover oncology · 2026Review
- Metabolic reprogramming and immunosenescence: a new sight for glioma therapy.Frontiers in cell and developmental biology · 2026Review
- Review
- Integrating of Machine Learning to Characterize Tumor-Infiltrating Immune Cell-Related Signature for Enhancing Prognosis for Glioma Patients.Biological procedures online · 2025Article
- Environmental Hazards and Glial Brain Tumors: Association or Causation?International journal of molecular sciences · 2025Review
- lncRNABiomedicines · 2025Article
- The role of regulatory T cells in central nervous system diseases in dogs: fighting with a double-edged sword toward translational discoveries.American journal of translational research · 2025Review
- Exploring the Role of Immune Cells in Glioma: Causal Associations and Clinical Implications.International journal of medical sciences · 2025Article
- Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment.Frontiers in immunology · 2025Review
- Going viral: targeting glioblastoma using oncolytic viruses.Immunotherapy advances · 2025Review
- Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements.CNS & neurological disorders drug targets · 2025Article
- Early Detection of Glioma: Investigating Inflammatory Markers (CRP), Kidney, and Liver Function.CNS & neurological disorders drug targets · 2025Article
- B cell immunity and therapeutic opportunities in brain metastases.Frontiers in immunology · 2025Review
- Co-evolution of glioma and immune microenvironment.Journal for immunotherapy of cancer · 2024Review
- TheJournal of personalized medicine · 2024Article
- Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioma progression is a complex process controlled by molecular factors that coordinate the crosstalk between tumor cells and components of the tumor microenvironment (TME). Among these, immune cells play a critical role in cancer survival and progression. The complex interplay between cancer cells and the immune TME influences the outcome of immunotherapy and other anti-cancer therapies. Here, we present an updated view of the pro- and anti-tumor activities of the main myeloid and lymphocyte cell populations in the glioma TME. We review the underlying mechanisms involved in crosstalk between cancer cells and immune cells that enable gliomas to evade the immune system and co-opt these cells for tumor growth. Lastly, we discuss the current and experimental therapeutic options being developed to revert the immunosuppressive activity of the glioma TME. Knowledge of the complex interplay that elapses between tumor and immune cells may help develop new combination treatments able to overcome tumor immune evasion mechanisms and enhance response to immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.